Company / Current Liabilities
Idexx Laboratories Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$1.1B
FY2025
5-year range
$763.6M / $1.2B
FY2021-FY2025
Trend
+7.6%
vs FY2024
Sector context
#47 of 165
Health Care
What the data says
At $1.1B, Idexx Laboratories's current liabilities ranks #119 of 165 in the Health Care sector. Current Liabilities has fluctuated over the past 10 years, ranging from $583M in FY2020 to $1.2B in FY2022.
Based on SEC 10-K filings.
$1.1B in FY2025 with a 5-year CAGR of +14.5%.
Increased from $952M to $1.1B over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -2.4%
- 5-Year CAGR
- +14.5%
- 10-Year CAGR
- -
Sector benchmark
#119 of 165 in Health CareTop 72% of 165This company $1.1B Sector average $4.4B
▼
-74.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +14.5%, indicating consistent growth.
- In FY2025, current liabilities increased 7.6% year-over-year.
- Ranks #47 out of 165 companies in the Health Care sector.
- Peak current liabilities was recorded in FY2022.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 4.60 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 65.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1B | +7.6% |
| FY2024 | $1.1B | +12.2% |
| FY2023 | $951.5M | -23.0% |
| FY2022 | $1.2B | +61.8% |
| FY2021 | $763.6M | +31.0% |
| FY2020 | $582.8M | -19.7% |
| FY2019 | $725.3M | -5.9% |
| FY2018 | $770.4M | -23.3% |
| FY2017 | $1.0B | +7.5% |
| FY2016 | $934.6M | +9.1% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026